Tada Keiichiro, Nishioka Kotoe, Kikuchi Yasuko, Niwa Takayoshi, Seto Yasuyuki
Department of Breast and Endocrine Surgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Breast Cancer. 2017 Jul;24(4):502-504. doi: 10.1007/s12282-017-0787-7. Epub 2017 Jun 5.
In 2014, the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) reported that post-mastectomy radiation therapy (PMRT) for breast cancer patients with 1-3 cancer-positive lymph nodes is associated with a survival benefit. However, it is not known whether this applies to Japanese patients in daily clinical practice, because this conclusion was based on the results of older, western trials. Therefore, we studied the differences between PMRT results in western breast cancer patients and current practice in Japanese patients. Although we identified three differences, they do not appear to strongly impact the results of EBCTCG. We conclude that Japanese breast cancer patients with 1-3 positive lymph nodes should receive PMRT in daily clinical practice.
2014年,早期乳腺癌试验协作组(EBCTCG)报告称,对于有1 - 3个癌转移阳性淋巴结的乳腺癌患者,乳房切除术后放射治疗(PMRT)可带来生存获益。然而,在日常临床实践中,这一结论是否适用于日本患者尚不清楚,因为该结论是基于早期西方试验的结果。因此,我们研究了西方乳腺癌患者PMRT结果与日本患者当前临床实践之间的差异。尽管我们发现了三点差异,但它们似乎并未对EBCTCG的结果产生强烈影响。我们得出结论,在日常临床实践中,有1 - 3个阳性淋巴结的日本乳腺癌患者应接受PMRT。